Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company that develops RNA-based medicines to restore protein expression in severe genetic diseases. Its news flow is closely tied to the progress of its antisense oligonucleotide programs, particularly zorevunersen for Dravet syndrome and STK-002 for Autosomal Dominant Optic Atrophy (ADOA).
Investors following STOK news can expect regular updates on clinical development milestones. These include announcements on the global Phase 3 EMPEROR study of zorevunersen in children and adolescents with Dravet syndrome, multi-year data from open-label extension studies, and analyses comparing treated patients with natural history data. Stoke also reports on natural history research such as the FALCON study in ADOA, which informs the design of interventional trials like the OSPREY Phase 1 study of STK-002.
Regulatory and collaboration developments are another important category of news. Stoke highlights regulatory designations for zorevunersen, including orphan drug, rare pediatric disease, and Breakthrough Therapy Designation, as well as its strategic collaboration with Biogen, under which the companies jointly advance zorevunersen for Dravet syndrome with defined regional commercialization rights.
Corporate and financial updates appear in press releases and are often paired with SEC filings. These items cover quarterly financial results, cash runway commentary, stock-based inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in major healthcare and investor conferences. Webcasts and conference calls for analysts and investors are also announced through news releases.
For anyone researching STOK, the news stream provides context on how Stoke Therapeutics is advancing its TANGO antisense platform, executing clinical trials in rare neurological and ophthalmic diseases, and managing its partnerships and capital to support ongoing development.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on treating genetic diseases, announced that CEO Edward M. Kaye will present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 3:20 p.m. ET. A live webcast will be available on the company's website, with a replay accessible for 30 days after the event. Stoke aims to develop solutions for genetic diseases through precise protein expression upregulation, targeting conditions caused by mutated genes. For more details, visit Stoke Therapeutics.
Stoke Therapeutics, Inc. (Nasdaq: STOK), a clinical-stage biotechnology firm, announced that CEO Edward M. Kaye, M.D., will participate in a fireside chat during the 29th Annual Credit Suisse Virtual Healthcare Conference on November 9, 2020, at 10:15 a.m. ET. This session aims to highlight the company's innovative approach to treating genetic diseases by precisely upregulating protein expression. Investors can access a live audio webcast of the chat on Stoke’s website, which will also feature a replay for 30 days.
Stoke Therapeutics (Nasdaq: STOK) is advancing its Phase 1/2a MONARCH study for STK-001, targeting Dravet syndrome, after receiving FDA approval to add higher dose levels for evaluation. The study will now assess doses of 10 mg, 20 mg, and 30 mg, with studies above 30 mg on hold. No adverse effects were noted in preclinical repeat-dose tests. The company aims to submit a protocol amendment for a multiple ascending dose segment. STK-001, an investigational drug, aims to adjust NaV1.1 protein levels, potentially modifying the disease's course.